Asia-Pacific Lipidomics Equipment Market is expected to reach US$ 614.01 million by 2028

At 15.3% CAGR, the Asia-Pacific Lipidomics Equipment Market is speculated to be worth US$ 614.01 million by 2028, says Business Market Insights 

According to Business Market Insights’ research, the Asia-Pacific lipidomics equipment market was valued at US$ 261.28 million in 2022 and is expected to reach US$ 614.01 million by 2028, registering a CAGR of 15.3% from 2022 to 2028. Growing applications of lipidomics in biomedical sciences and escalating government & market players investment in emerging countries are the critical factors attributed to the Asia-Pacific lipidomics equipment market expansion.        

Lipidomics, an emerging discipline of biomedical sciences, involves the characterization of complex lipidomes. It is a quantitative and complete depiction of a set of lipid species present in an organism. The lipidome characterization is based on a system-level quantitation and the detection of several networks & pathways of cellular lipids, along with their interaction with other moieties and proteins. Determining lipid profiles and comparing the profiles obtained for two physiologically linked conditions can help understand lipid metabolism pathways, which further can be employed for the development of diagnostic methods for cancer, cardiovascular disorders, eye diseases, and other diseases. In February 2022, researchers from the Peking University Health Science Center in Beijing performed liquid chromatography-mass spectrometry (LCMS)-based targeted lipidomics assay on 311 participants. This study represents the potential application of Lung Cancer Artificial Intelligence Detector v2.0 for lipidomics-based large-scale population screening, particularly for populations with a high risk of lung cancer. The researchers identified nine lipid profiles associated with early-stage lung cancer during this study.  Lipidomics plays a pivotal role in pharmacological research, especially in new drug discovery and development processes. It is also applied for toxicity evaluation, molecule screening, preclinical testing, etc. For example, de novo lipogenesis inhibitors are of major interest among researchers due to their pro-apoptotic effects on cancerous tissues. Lipidomics can also be used to screen such anticancer drug candidates for their ability to inhibit de novo lipid synthesis and for identifying novel drug efficacy biomarkers. Thus, a wide range of applications of lipidomics in biomedical sciences boosts the demand for lipidomics equipment, thereby propelling the Asia-Pacific lipidomics equipment market growth.  

On the contrary, premium product pricing hurdles the growth of Asia-Pacific lipidomics equipment market.   

Based on type, the Asia-Pacific lipidomics equipment market is bifurcated into targeted and untargeted. The targeted segment held 62.5% share of Asia-Pacific lipidomics equipment market in 2022, amassing US$ 163.29 million. It is projected to garner US$ 381.03 million by 2028 to expand at 15.2% CAGR during 2022–2028.  

Based on offerings, the Asia-Pacific lipidomics equipment market is segmented into MS-based lipidomics techniques, assays for lipid metabolism, lipid flux using heavy isotope-labeled precursors, software & services, and others. The MS-based lipidomics techniques segment held 66.5% share of Asia-Pacific lipidomics equipment market in 2022, amassing US$ 173.75 million. It is projected to garner US$ 406.66 million by 2028 to expand at 15.2% CAGR during 2022–2028. The MS-based lipidomics techniques segment is further categorized into mass spectrometers equipped with ion sources (turbo-) ESI/nano-ESI/APCI, autosamplers, micropumps, UV detectors, UPLC, variable-length fluorescence detectors, and others.    

Based on services, the Asia-Pacific lipidomics equipment market has been segmented into biomarker identification, bioinformatic analysis & data interpretation, molecular analysis of a broad spectrum of phospholipids (lipid fingerprinting), analysis & identification of unusual lipids, semiquantitative & quantitative analysis, lipid flux studies, and others. The biomarker identification segment held 29.7% share of Asia-Pacific lipidomics equipment market in 2022, amassing US$ 77.56 million. It is projected to garner US$ 205.35 million by 2028 to expand at 15.2% CAGR during 2022–2028.      

Based on end user, the Asia-Pacific lipidomics equipment market is segmented into molecular research, cellular research, clinical research, tissue & organ research, data research, organism research, technical services & prototyping, production, and others. The molecular research segment held 27.3% share of Asia-Pacific lipidomics equipment market in 2022, amassing US$ 71.30 million. It is projected to garner US$ 168.89 million by 2028 to expand at 15.5% CAGR during 2022–2028.

Based on country, the Asia-Pacific lipidomics equipment market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Our regional analysis states that China captured 28.3% share of Asia-Pacific lipidomics equipment market in 2022. It was assessed at US$ 73.90 million in 2022 and is likely to hit US$ 172.72 million by 2028, exhibiting a CAGR of 15.2% during the forecast period.

Key players dominating the Asia-Pacific lipidomics equipment market are Agilent Technologies, Inc.; Bruker; Cayman Chemical; Creative Proteomics; IonBench; PerkinElmer Inc.; Sciex; Shimadzu Corporation.; and Thermo Fisher Scientific Inc., among others.

• In Sep 2021, Thermofisher Scientific launched new Vanish Neo UHPLC System which will transform how scientists perform proteomics studies by providing the long-term robustness and flow-range versatility required for deep and fast LC-MS profiling of thousands of proteomes, while coupled with PepMap Columns and high-resolution accurate mass (HRAM) systems.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com